Glaucoma 360: Getting updated with Glauconix Biosciences


Glauconix Biosciences' Kimberly Southern (CEO) and Karen Torrejon, PhD (CSO) sit down with Ophthalmology Times'® Sheryl Stevenson to discuss the company's role in using innovative platform technology to reduce the cost of ophthalmic drug development as well as what models are in their 2020 pipeline for the glaucoma and other eye-related diseases space, during this year's Glaucoma 360 annual meeting in San Francisco, California.

See more Glaucoma 360 content here. 


Related Videos
ViaLase seeks to disrupt glaucoma treatment paradigm with new femtosecond laser treatment
Contralateral eye study investigates iStent vs Hydrus stent for glaucoma
Robot-assisted micro interventional glaucoma surgery reduces surgeon's tremors
Related Content
© 2023 MJH Life Sciences

All rights reserved.